---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-004129"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:23:33.700281+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Climb Bio licenses MIL116 antibodies from Mabworks; reports $212.9M cash, runway through 2027

## Summary
- Upfront $9M to Mabworks; up to $30M development/regulatory milestones for first indication.
- Up to $832M commercial milestones across all products; tiered low-to mid-single-digit royalties.
- Preliminary cash $212.9M and ~67.3M shares outstanding as of Dec 31, 2024.
- Existing cash expected to fund operations, including budoprutug and CLYM116, through 2027.
- Exclusive rights to MIL116 (CLYM116) outside China; non-exclusive rights for global trials.

## SEC filing metadata
- accession: 0001193125-25-004129
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312525004129/0001193125-25-004129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312525004129/d851032d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-004129
- JSON: https://secwatch.observer/filing/0001193125-25-004129.json
- Plain text: https://secwatch.observer/filing/0001193125-25-004129.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.